Novartis sickle cell drug crizanlizumab secures speedy USFDA review Medical Dialogues Bureau17 July 2019 3:56 AMNovartis submitted the application for crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) and...